{"filing":{"accession_number":"0001493152-26-026965","cik":"0001412486","ticker":"COCP","company_name":"Cocrystal Pharma, Inc.","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226026965/form8-k.htm"},"events":[{"id":7239,"run_id":6353,"accession_number":"0001493152-26-026965","anchor_item_number":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the appointment of James Sapirstein as Chief Executive Officer, announced via press release on June 3, 2026. This is a material executive appointment at the C-suite level that would affect a reasonable investor's assessment of the company's leadership and direction.","company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","filing_date":"2026-06-03","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":4068,"accession_number":"0001493152-26-026965","item_number":null,"item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of James Sapirstein as Chief Executive Officer, announced via press release on June 3, 2026. This is a material executive appointment at the C-suite level that would affect a reasonable investor's assessment of the company's leadership and direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:45:26.867853+00:00","company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","filing_date":"2026-06-03"}]}